{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T21:22:25Z","timestamp":1760908945688},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,8,20]],"date-time":"2015-08-20T00:00:00Z","timestamp":1440028800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2015,8,20]],"date-time":"2015-08-20T00:00:00Z","timestamp":1440028800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Salivary duct carcinoma (SDC) is an uncommon, but aggressive malignant tumor with a high mortality rate. Herein, we reported the detection of somatic <jats:italic>KRAS<\/jats:italic> A146T and Q61H mutations in 2 out of 4 (50%) sarcomatoid SDC variants. Transgenic mice carrying the human oncogenic KRAS<jats:sup>G12V<\/jats:sup>, which spatiotemporal activation by tamoxifen (TAM)-inducible Cre recombinase <jats:italic>Ela-CreERT<\/jats:italic> in the submandibular gland (SMG) ductal cells, was established and characterized. Visible carcinoma was detected as early as day-15 following oncogenic KRAS<jats:sup>G12V<\/jats:sup> induction alone and these tumors proliferate rapidly with a median survival of 28-days accompanied with histological reminiscences to human sarcomatoid SDC variants. Moreover, these tumors were resistant to cetuximab treatment despite augmented EGFR signaling, attesting its malignancy. Our findings suggest that <jats:italic>LGL-KRas<\/jats:italic><jats:sup><jats:italic>G12V<\/jats:italic><\/jats:sup><jats:italic>;Ela-CreERT<\/jats:italic> transgenic mice could serve as a useful preclinical model for investigating underlying mechanisms and developing potential therapies.<\/jats:p>","DOI":"10.1038\/srep13347","type":"journal-article","created":{"date-parts":[[2015,8,20]],"date-time":"2015-08-20T09:30:13Z","timestamp":1440063013000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Ductal activation of oncogenic KRAS alone induces sarcomatoid phenotype"],"prefix":"10.1038","volume":"5","author":[{"given":"Yong","family":"Fu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zobeida","family":"Cruz-Monserrate","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Helen Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yiyin","family":"Chung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baoan","family":"Ji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Szu-min","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Vonderfecht","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Craig D.","family":"Logsdon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chien-Feng","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David K.","family":"Ann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,8,20]]},"reference":[{"key":"BFsrep13347_CR1","doi-asserted-by":"publisher","first-page":"2526","DOI":"10.1002\/cncr.21116","volume":"103","author":"M Jaehne","year":"2005","unstructured":"Jaehne, M. et al. Clinical and immunohistologic typing of salivary duct carcinoma: a report of 50 cases. Cancer. 103, 2526\u20132533 (2005).","journal-title":"Cancer."},{"key":"BFsrep13347_CR2","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/S0194-5998(03)01386-X","volume":"129","author":"AS Hosal","year":"2003","unstructured":"Hosal, A. S., Fan, C., Barnes, L. & Myers, E. N. Salivary duct carcinoma. Otolaryngol Head Neck Surg. 129, 720\u2013725 (2003).","journal-title":"Otolaryngol Head Neck Surg."},{"key":"BFsrep13347_CR3","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1097\/PAS.0000000000000410","volume":"39","author":"SI Chiosea","year":"2015","unstructured":"Chiosea, S. I. et al. Molecular Characterization of Apocrine Salivary Duct Carcinoma. Am J Surg Pathol. 39, 744\u2013752 (2015).","journal-title":"Am J Surg Pathol."},{"key":"BFsrep13347_CR4","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1097\/PAS.0000000000000413","volume":"39","author":"L Williams","year":"2015","unstructured":"Williams, L. et al. Salivary duct carcinoma: the predominance of apocrine morphology, prevalence of histologic variants and androgen receptor expression. Am J Surg Pathol. 39, 705\u2013713 (2015).","journal-title":"Am J Surg Pathol."},{"key":"BFsrep13347_CR5","first-page":"454","volume":"29","author":"R Gal","year":"1985","unstructured":"Gal, R., Strauss, M., Zohar, Y. & Kessler, E. Salivary duct carcinoma of the parotid gland. Cytologic and histopathologic study. Acta Cytol. 29, 454\u2013456 (1985).","journal-title":"Acta Cytol."},{"key":"BFsrep13347_CR6","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1034\/j.1601-0825.2002.02870.x","volume":"8","author":"PM Speight","year":"2002","unstructured":"Speight, P. M. & Barrett, A. W. Salivary gland tumours. Oral Dis. 8, 229\u2013240 (2002).","journal-title":"Oral Dis."},{"key":"BFsrep13347_CR7","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1002\/(SICI)1097-0142(19960115)77:2<223::AID-CNCR1>3.0.CO;2-N","volume":"77","author":"JE Lewis","year":"1996","unstructured":"Lewis, J. E., McKinney, B. C., Weiland, L. H., Ferreiro, J. A. & Olsen, K. D. Salivary duct carcinoma. Clinicopathologic and immunohistochemical review of 26 cases. Cancer. 77, 223\u2013230 (1996).","journal-title":"Cancer."},{"key":"BFsrep13347_CR8","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1097\/PAS.0b013e3182880d5a","volume":"37","author":"CC Griffith","year":"2013","unstructured":"Griffith, C. C., Seethala, R. R., Luvison, A., Miller, M. & Chiosea, S. I. PIK3CA mutations and PTEN loss in salivary duct carcinomas. Am J Surg Pathol. 37, 1201\u20131207 (2013).","journal-title":"Am J Surg Pathol."},{"key":"BFsrep13347_CR9","first-page":"810487","volume":"2014","author":"W Qiu","year":"2014","unstructured":"Qiu, W. et al. Oncogenic PIK3CA mutation and dysregulation in human salivary duct carcinoma. Biomed Res Int. 2014, 810487 (2014).","journal-title":"Biomed Res Int."},{"key":"BFsrep13347_CR10","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1186\/s12967-014-0299-6","volume":"12","author":"BM Ku","year":"2014","unstructured":"Ku, B. M. et al. High-throughput profiling identifies clinically actionable mutations in salivary duct carcinoma. J Transl Med. 12, 299 (2014).","journal-title":"J Transl Med."},{"key":"BFsrep13347_CR11","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1158\/1078-0432.CCR-12-1842","volume":"19","author":"V Nardi","year":"2013","unstructured":"Nardi, V. et al. Detection of novel actionable genetic changes in salivary duct carcinoma helps direct patient treatment. Clin Cancer Res. 19, 480\u2013490 (2013).","journal-title":"Clin Cancer Res."},{"key":"BFsrep13347_CR12","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1111\/his.12152","volume":"63","author":"A Bahrami","year":"2013","unstructured":"Bahrami, A., Perez-Ordonez, B., Dalton, J. D. & Weinreb, I. An analysis of PLAG1 and HMGA2 rearrangements in salivary duct carcinoma and examination of the role of precursor lesions. Histopathology. 63, 250\u2013262 (2013).","journal-title":"Histopathology."},{"key":"BFsrep13347_CR13","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1097\/00000478-200004000-00014","volume":"24","author":"CY Fan","year":"2000","unstructured":"Fan, C. Y., Wang, J. & Barnes, E. L. Expression of androgen receptor and prostatic specific markers in salivary duct carcinoma: an immunohistochemical analysis of 13 cases and review of the literature. Am J Surg Pathol. 24, 579\u2013586 (2000).","journal-title":"Am J Surg Pathol."},{"key":"BFsrep13347_CR14","doi-asserted-by":"publisher","first-page":"e473","DOI":"10.1200\/JCO.2010.32.8351","volume":"29","author":"HC Jaspers","year":"2011","unstructured":"Jaspers, H. C. et al. Androgen receptor-positive salivary duct carcinoma: a disease entity with promising new treatment options. J Clin Oncol. 29, e473\u2013476 (2011).","journal-title":"J Clin Oncol."},{"key":"BFsrep13347_CR15","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1111\/j.1365-2559.2012.04252.x","volume":"61","author":"S Di Palma","year":"2012","unstructured":"Di Palma, S. et al. Salivary duct carcinomas can be classified into luminal androgen receptor-positive, HER2 and basal-like phenotypes. Histopathology. 61, 629\u2013643 (2012).","journal-title":"Histopathology."},{"key":"BFsrep13347_CR16","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s10147-014-0674-6","volume":"20","author":"T Masubuchi","year":"2015","unstructured":"Masubuchi, T. et al. Clinicopathological significance of androgen receptor, HER2, Ki-67 and EGFR expressions in salivary duct carcinoma. Int J Clin Oncol. 20, 35\u201344 (2015).","journal-title":"Int J Clin Oncol."},{"key":"BFsrep13347_CR17","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1158\/2159-8290.CD-13-0900","volume":"4","author":"TL Yuan","year":"2014","unstructured":"Yuan, T. L. et al. Development of siRNA payloads to target KRAS-mutant cancer. Cancer Discov. 4, 1182\u20131197 (2014).","journal-title":"Cancer Discov."},{"key":"BFsrep13347_CR18","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1038\/nrd4389","volume":"13","author":"AD Cox","year":"2014","unstructured":"Cox, A. D., Fesik, S. W., Kimmelman, A. C., Luo, J. & Der, C. J. Drugging the undruggable RAS: Mission Possible? Nat Rev Drug Discov. 13, 828\u2013851 (2014).","journal-title":"Nat Rev Drug Discov."},{"key":"BFsrep13347_CR19","doi-asserted-by":"publisher","first-page":"9143","DOI":"10.1158\/0008-5472.CAN-10-1758","volume":"70","author":"CR Diegel","year":"2010","unstructured":"Diegel, C. R., Cho, K. R., El-Naggar, A. K., Williams, B. O. & Lindvall, C. Mammalian target of rapamycin-dependent acinar cell neoplasia after inactivation of Apc and Pten in the mouse salivary gland: implications for human acinic cell carcinoma. Cancer Res. 70, 9143\u20139152 (2010).","journal-title":"Cancer Res."},{"key":"BFsrep13347_CR20","doi-asserted-by":"publisher","first-page":"4544","DOI":"10.1158\/0008-5472.CAN-04-4041","volume":"65","author":"J Declercq","year":"2005","unstructured":"Declercq, J. et al. Salivary gland tumors in transgenic mice with targeted PLAG1 proto-oncogene overexpression. Cancer Res. 65, 4544\u20134553 (2005).","journal-title":"Cancer Res."},{"key":"BFsrep13347_CR21","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.2353\/ajpath.2006.050847","volume":"168","author":"AR Raimondi","year":"2006","unstructured":"Raimondi, A. R., Vitale-Cross, L., Amornphimoltham, P., Gutkind, J. S. & Molinolo, A. Rapid Development of Salivary Gland Carcinomas upon Conditional Expression of K-ras Driven by the Cytokeratin 5 Promoter. The American Journal of Pathology. 168, 1654\u20131665 (2006).","journal-title":"The American Journal of Pathology."},{"key":"BFsrep13347_CR22","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1038\/labinvest.2013.62","volume":"93","author":"AL Simons","year":"2013","unstructured":"Simons, A. L. et al. The Justy mutant mouse strain produces a spontaneous murine model of salivary gland cancer with myoepithelial and basal cell differentiation. Lab Invest. 93, 711\u2013719 (2013).","journal-title":"Lab Invest."},{"key":"BFsrep13347_CR23","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.ccr.2005.04.023","volume":"7","author":"SR Hingorani","year":"2005","unstructured":"Hingorani, S. R. et al. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell. 7, 469\u2013483 (2005).","journal-title":"Cancer Cell."},{"key":"BFsrep13347_CR24","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1158\/0008-5472.CAN-11-3132","volume":"72","author":"DJ Mulholland","year":"2012","unstructured":"Mulholland, D. J. et al. Pten loss and RAS\/MAPK activation cooperate to promote EMT and metastasis initiated from prostate cancer stem\/progenitor cells. Cancer Res. 72, 1878\u20131889 (2012).","journal-title":"Cancer Res."},{"key":"BFsrep13347_CR25","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1309\/5J4008QRY1HWW5W4","volume":"122","author":"T Nagao","year":"2004","unstructured":"Nagao, T. et al. Sarcomatoid variant of salivary duct carcinoma: clinicopathologic and immunohistochemical study of eight cases with review of the literature. Am J Clin Pathol. 122, 222\u2013231 (2004).","journal-title":"Am J Clin Pathol."},{"key":"BFsrep13347_CR26","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1002\/dvg.20411","volume":"46","author":"B Ji","year":"2008","unstructured":"Ji, B. et al. Robust acinar cell transgene expression of CreErT via BAC recombineering. Genesis. 46, 390\u2013395 (2008).","journal-title":"Genesis."},{"key":"BFsrep13347_CR27","unstructured":"Cruz-Monserrate, Z., Ji, B., El-Naggar, A. K. & Logsdon, C. D. Novel transgenic animal model of salivary gland tumors. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; 1538-7445.AM2012-2357 (2012)."},{"key":"BFsrep13347_CR28","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1002\/dvg.20335","volume":"45","author":"MD Muzumdar","year":"2007","unstructured":"Muzumdar, M. D., Tasic, B., Miyamichi, K., Li, L. & Luo, L. A global double-fluorescent Cre reporter mouse. Genesis. 45, 593\u2013605 (2007).","journal-title":"Genesis."},{"key":"BFsrep13347_CR29","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1038\/5007","volume":"21","author":"P Soriano","year":"1999","unstructured":"Soriano, P. Generalized lacZ expression with the ROSA26 Cre reporter strain. Nat Genet. 21, 70\u201371 (1999).","journal-title":"Nat Genet."},{"key":"BFsrep13347_CR30","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1053\/j.gastro.2009.05.052","volume":"137","author":"B Ji","year":"2009","unstructured":"Ji, B. et al. Ras activity levels control the development of pancreatic diseases. Gastroenterology. 137, 1072\u20131082 (2009).","journal-title":"Gastroenterology."},{"key":"BFsrep13347_CR31","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1056\/NEJMoa040938","volume":"350","author":"TJ Lynch","year":"2004","unstructured":"Lynch, T. J. et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 350, 2129\u20132139 (2004).","journal-title":"N Engl J Med."},{"key":"BFsrep13347_CR32","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1126\/science.1099314","volume":"304","author":"JG Paez","year":"2004","unstructured":"Paez, J. G. et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 304, 1497\u20131500 (2004).","journal-title":"Science."},{"key":"BFsrep13347_CR33","doi-asserted-by":"publisher","first-page":"5267","DOI":"10.1158\/1078-0432.CCR-09-0888","volume":"15","author":"DM Jackman","year":"2009","unstructured":"Jackman, D. M. et al. Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials. Clin Cancer Res. 15, 5267\u20135273 (2009).","journal-title":"Clin Cancer Res."},{"key":"BFsrep13347_CR34","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1200\/JCO.2008.20.8397","volume":"27","author":"C Bokemeyer","year":"2009","unstructured":"Bokemeyer, C. et al. Fluorouracil, leucovorin and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol. 27, 663\u2013671 (2009).","journal-title":"J Clin Oncol."},{"key":"BFsrep13347_CR35","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1056\/NEJMoa0805019","volume":"360","author":"E Van Cutsem","year":"2009","unstructured":"Van Cutsem, E. et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 360, 1408\u20131417 (2009).","journal-title":"N Engl J Med."},{"key":"BFsrep13347_CR36","first-page":"115","volume":"172","author":"NR Jayasinghe","year":"1990","unstructured":"Jayasinghe, N. R., Cope, G. H. & Jacob, S. Morphometric studies on the development and sexual dimorphism of the submandibular gland of the mouse. J Anat. 172, 115\u2013127 (1990).","journal-title":"J Anat."},{"key":"BFsrep13347_CR37","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.ccr.2012.07.024","volume":"22","author":"CM Ardito","year":"2012","unstructured":"Ardito, C. M. et al. EGF receptor is required for KRAS-induced pancreatic tumorigenesis. Cancer Cell. 22, 304\u2013317 (2012).","journal-title":"Cancer Cell."},{"key":"BFsrep13347_CR38","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.ccr.2012.08.001","volume":"22","author":"C Navas","year":"2012","unstructured":"Navas, C. et al. EGF receptor signaling is essential for k-ras oncogene-driven pancreatic ductal adenocarcinoma. Cancer Cell. 22, 318\u2013330 (2012).","journal-title":"Cancer Cell."},{"key":"BFsrep13347_CR39","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1056\/NEJMoa0804385","volume":"359","author":"CS Karapetis","year":"2008","unstructured":"Karapetis, C. S. et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 359, 1757\u20131765 (2008).","journal-title":"N Engl J Med."},{"key":"BFsrep13347_CR40","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1038\/nature11156","volume":"486","author":"S Misale","year":"2012","unstructured":"Misale, S. et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature. 486, 532\u2013536 (2012).","journal-title":"Nature."},{"key":"BFsrep13347_CR41","first-page":"1255","volume":"Vol. 2","author":"E Hanna","year":"1998","unstructured":"Hanna, E. & Suen, J. Neoplasms of the salivary glands in Otolaryngology-Head and Neck Surgery 3rd edn, Vol. 2 (eds Cummings, C. W. et al. ) 1255\u20131302 (Mosby, 1998).","journal-title":"Neoplasms of the salivary glands in Otolaryngology-Head and Neck Surgery 3rd edn"},{"key":"BFsrep13347_CR42","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1267\/ahc.12013","volume":"45","author":"O Amano","year":"2012","unstructured":"Amano, O., Mizobe, K., Bando, Y. & Sakiyama, K. Anatomy and histology of rodent and human major salivary glands: overview of the Japan salivary gland society-sponsored workshop. Acta Histochem Cytochem. 45, 241\u2013250 (2012).","journal-title":"Acta Histochem Cytochem."},{"key":"BFsrep13347_CR43","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1038\/nature13638","volume":"515","author":"D Di Mitri","year":"2014","unstructured":"Di Mitri, D. et al. Tumour-infiltrating Gr-1+ myeloid cells antagonize senescence in cancer. Nature. 515, 134\u2013137 (2014).","journal-title":"Nature."},{"key":"BFsrep13347_CR44","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1083\/jcb.201009094","volume":"192","author":"F Rodier","year":"2011","unstructured":"Rodier, F. & Campisi, J. Four faces of cellular senescence. J Cell Biol. 192, 547\u2013556 (2011).","journal-title":"J Cell Biol."},{"key":"BFsrep13347_CR45","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1038\/onc.2012.619","volume":"33","author":"H Huang","year":"2014","unstructured":"Huang, H. et al. Oncogenic K-Ras requires activation for enhanced activity. Oncogene. 33, 532\u2013535 (2014).","journal-title":"Oncogene."},{"key":"BFsrep13347_CR46","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/BF00225536","volume":"186","author":"T Barka","year":"1978","unstructured":"Barka, T., Gresik, E. W. & vad der Noen, H. Stimulation of secretion of epidermal growth factor and amylase of cyclocytidine. Cell Tissue Res. 186, 269\u2013278 (1978).","journal-title":"Cell Tissue Res."},{"key":"BFsrep13347_CR47","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/0006-8993(85)90595-5","volume":"332","author":"L Aloe","year":"1985","unstructured":"Aloe, L., Cozzari, C. & Levi-Montalcini, R. Cyclocytidine-induced release of nerve growth factor from mouse submandibular glands enhances regeneration of sympathetic fibers in adult mice. Brain Res. 332, 259\u2013265 (1985).","journal-title":"Brain Res."},{"key":"BFsrep13347_CR48","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1111\/j.1469-7580.2006.00568.x","volume":"208","author":"MS Lantini","year":"2006","unstructured":"Lantini, M. S., Cossu, M., Isola, M., Piras, M. & Piludu, M. Subcellular localization of epidermal growth factor receptor in human submandibular gland. J Anat. 208, 595\u2013599 (2006).","journal-title":"J Anat."},{"key":"BFsrep13347_CR49","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.critrevonc.2009.10.004","volume":"74","author":"M Guzzo","year":"2010","unstructured":"Guzzo, M. et al. Major and minor salivary gland tumors. Crit Rev Oncol Hematol. 74, 134\u2013148 (2010).","journal-title":"Crit Rev Oncol Hematol."},{"key":"BFsrep13347_CR50","doi-asserted-by":"publisher","first-page":"2673","DOI":"10.1200\/JCO.2005.05.3025","volume":"24","author":"SA Laurie","year":"2006","unstructured":"Laurie, S. A. & Licitra, L. Systemic therapy in the palliative management of advanced salivary gland cancers. J Clin Oncol. 24, 2673\u20132678 (2006).","journal-title":"J Clin Oncol."},{"key":"BFsrep13347_CR51","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1007\/s11912-012-0220-5","volume":"14","author":"D Bell","year":"2012","unstructured":"Bell, D. & Hanna, E. Y. Salivary gland cancers: biology and molecular targets for therapy. Curr Oncol Rep. 14, 166\u2013174 (2012).","journal-title":"Curr Oncol Rep."},{"key":"BFsrep13347_CR52","doi-asserted-by":"publisher","first-page":"2845","DOI":"10.1002\/stem.1793","volume":"32","author":"S Krishnamurthy","year":"2014","unstructured":"Krishnamurthy, S. et al. Endothelial interleukin-6 defines the tumorigenic potential of primary human cancer stem cells. Stem Cells. 32, 2845\u20132857 (2014).","journal-title":"Stem Cells."},{"key":"BFsrep13347_CR53","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/nrc3106","volume":"11","author":"Y Pylayeva-Gupta","year":"2011","unstructured":"Pylayeva-Gupta, Y., Grabocka, E. & Bar-Sagi, D. RAS oncogenes: weaving a tumorigenic web. Nat Rev Cancer. 11, 761\u2013774 (2011).","journal-title":"Nat Rev Cancer."},{"key":"BFsrep13347_CR54","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/S1535-6108(03)00191-0","volume":"4","author":"C Guerra","year":"2003","unstructured":"Guerra, C. et al. Tumor induction by an endogenous K-ras oncogene is highly dependent on cellular context. Cancer Cell. 4, 111\u2013120 (2003).","journal-title":"Cancer Cell."},{"key":"BFsrep13347_CR55","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1073\/pnas.0307203101","volume":"101","author":"BS Braun","year":"2004","unstructured":"Braun, B. S. et al. Somatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder. Proc Natl Acad Sci USA 101, 597\u2013602 (2004).","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFsrep13347_CR56","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1038\/sj.leu.2403272","volume":"18","author":"JP Perentesis","year":"2004","unstructured":"Perentesis, J. P. et al. RAS oncogene mutations and outcome of therapy for childhood acute lymphoblastic leukemia. Leukemia. 18, 685\u2013692 (2004).","journal-title":"Leukemia."},{"key":"BFsrep13347_CR57","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1038\/ng.211","volume":"40","author":"MD To","year":"2008","unstructured":"To, M. D. et al. Kras regulatory elements and exon 4A determine mutation specificity in lung cancer. Nat Genet. 40, 1240\u20131244 (2008).","journal-title":"Nat Genet."},{"key":"BFsrep13347_CR58","doi-asserted-by":"publisher","first-page":"3243","DOI":"10.1101\/gad.943001","volume":"15","author":"EL Jackson","year":"2001","unstructured":"Jackson, E. L. et al. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev. 15, 3243\u20133248 (2001).","journal-title":"Genes Dev."},{"key":"BFsrep13347_CR59","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1016\/j.oraloncology.2013.08.004","volume":"49","author":"KA Warner","year":"2013","unstructured":"Warner, K. A. et al. Characterization of tumorigenic cell lines from the recurrence and lymph node metastasis of a human salivary mucoepidermoid carcinoma. Oral Oncol. 49, 1059\u20131066 (2013).","journal-title":"Oral Oncol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep13347","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep13347.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep13347.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T22:23:34Z","timestamp":1672957414000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep13347"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8,20]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2015,10,16]]}},"alternative-id":["BFsrep13347"],"URL":"https:\/\/doi.org\/10.1038\/srep13347","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,8,20]]},"assertion":[{"value":"18 March 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"13347"}}